September 10, 2010 - New, Bright Prospects for Curcumin Int Immunopharmacol
Int Immunopharmacol. 2010 Sep 10. [Epub ahead of print]
Curcumin has bright prospects for the treatment of multiple sclerosis.
Xie L, Li XK, Takahara S.
Division for Radiation Safety and Immune Tolerance, National Research Institute for Child Health and Development, Tokyo, Japan; Department of Advanced Technology for Transplantation, Osaka University Graduate School of Medicine, Osaka, Japan.
Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system (CNS). It is associated with a variety of pathophysiological features, including breakdown of the blood-brain barrier (BBB), autoimmune attack, injury of axons and myelin sheaths. Th17 cells are considered as a key immunological player for the pathophysiological process of MS. Neuroprotective approaches work best prior to the initiation of damage, suggesting that some safe and effective prophylaxis would be highly desirable. Curcumin, a dietary spice from turmeric, has outstanding anti-inflammation and neuroprotective effects. Herein, we review key features of curcumin involved biology, pharmacology, and medicinal chemistry and discuss its potential relevance to pathophysiological progress of MS.
PMID: 20828641 [PubMed - as supplied by publisher]
EUROPHARMA USA LIBRARY DISCLAIMER
The research articles and study abstracts that you are about to view in the EuroPharma USA Library were prepared by independent authors and researchers. They are being reproduced on this site in their entirety. No such article or study abstract is intended to promote a particular manufacturer or brand of dietary supplement. This information is not intended to replace the advice of your health care practitioner. If you have any medical conditions, or are taking any prescription or nonprescription medications, see your physician and discuss all aspects of your treatment before altering or discontinuing any course of therapy. Accordingly, individuals must necessarily assume responsibility for their own actions, safety, and health, and the company is not liable or responsible for any loss, injury, or damage allegedly arising from any information posted on this cite.
THIS INFORMATION IS BEING PRESENTED PURSUANT TO SECTION 5 OF THE DIETARY SUPPLEMENT HEALTH AND EDUCATION ACT OF 1994-------THE "E" IN DSHEA—BROUGHT TO YOU AS A PUBLIC SERVICE BY EUROPHARMA USA.
